ISSN 1662-4009 (online)

ey0016.4-7 | New Perspectives | ESPEYB16

4.7. Idiopathic short stature and growth hormone sensitivity in prepubertal children

JGB Derraik , HL Miles , V Chiavaroli , PL Hofman , WS Cutfield

To read the full abstract: Clin Endocrinol. 2019;91:110–117.Idiopathic short stature (ISS) refers to a heterogeneous population of children with a height more than 2 SDS below the mean for age, sex, and population, in presence of normal birth size and body proportions, and without evidence of any identifiable cause. The use of next generation sequencing (NGS) has shown that a high p...

ey0018.3-9 | Congenital hypothyroidism | ESPEYB18

3.9. Newborn screening TSH values less than 15 mIU/L are not associated with long-term hypothyroidism or cognitive impairment

R West , J Hong , JGB Derraik , D Webster , NL Heather , PL Hofman

J Clin Endocrinol Metab. 2020;105:dgaa415. doi: 10.1210/clinem/dgaa415.The optimal cut-off for neonatal screening has long been a matter of debate. The optimal balance between optimal detection of cases and increase of false positive patients is difficult to define. Also, in the most recent guidelines for congenital hypothyroidism (see previous paper in this chapter 3.7), no precise cut-off...

ey0021.13-8 | Endocrinology | ESPEYB21

13.8. Experiences and challenges with congenital hypothyroidism newborn screening in Indonesia: a national cross-sectional survey

AB Pulungan , HA Puteri , M Faizi , PL Hofman , A Utari , JP Chanoine

Brief Summary: This cross-sectional survey of healthcare professionals and administrators in Indonesia investigated the many challenges raised during implementation of a national newborn screening program for congenital hypothyroidism (CH).Despite initiation of Newborn Screening (NBS) for CH in Indonesia between 2000 and 2010 and expansion more recently, only 2.3% of newborns were screened in 2022. This national survey aimed to identify barriers to wider...

ey0019.4-8 | Long-acting growth hormone (LAGH) | ESPEYB19

4.8. Weekly lonapegsomatropin in treatment-naive children with growth hormone deficiency: the phase 3 height trial

PS Thornton , AK Maniatis , E Aghajanova , E Chertok , E Vlachopapadopoulou , Z Lin , W Song , E Dam Christoffersen , VM Breinholt , T Kovalenko , E Giorgadze , M Korpal-Szczyrska , PL Hofman , DB Karpf , AD Shu , Beckert M. Michael

J Clin Endocrinol Metab, 2021. 106(11): p. 3184-3195. PMID: 34272849Brief Summary: This randomized, open-label, controlled, phase 3 trial compared the effects of once-weekly long-acting GH lonapegsomatropin versus daily GH in GHD children over a period of 52 weeks. Efficacy was evaluated by height velocity (HV) and height gain from baseline to end. The long-acting formulation showed not only non-inferiority but also superior efficacy compared to...

ey0020.2-9 | Long-Acting Growth Hormone (LAGH) | ESPEYB20

2.9. Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enliGHten trial 2-year results

AK Maniatis , SJ Casella , UM Nadgir , PL Hofman , P Saenger , ED Chertock , EM Aghajanova , M Korpal-Szczyrska , E Vlachopapadopoulou , O Malievskiy , T Chaychenko , M Cappa , W Song , M Mao , PH Mygind , AR Smith , SD Chessler , AS Komirenko , M Beckert , AD Shu , PS Thornton

Brief summary: This open-label extension trial enrolled all subjects completing the two previous phase 3 Lonapegsomatropin trials, heiGHt and fliGHt. The results confirm the efficacy of this LAGH formulation in improving height SDS, without major adverse events.Lonapegsomatropin is a long-acting GH consisting of 3 components: unmodified human GH (hGH), an inert glycol carrier, and a TransCon linker that transiently binds the other 2 components. The glyco...

ey0017.4-1 | Important for clinical practice | ESPEYB17

4.1. Diagnosis, genetics, and therapy of short stature in children: A growth hormone research society international perspective

PF Collett-Solberg , G Ambler , PF Backeljauw , M Bidlingmaier , BMK Biller , MCS Boguszewski , PT Cheung , CSY Choong , LE Cohen , P Cohen , A Dauber , CL Deal , C Gong , Y Hasegawa , AR Hoffman , PL Hofman , R Horikawa , AAL Jorge , A Juul , P Kamenicky , V Khadilkar , JJ Kopchick , B Kristrom , MdLA Lopes , X Luo , BS Miller , M Misra , I Netchine , S Radovick , MB Ranke , AD Rogol , RG Rosenfeld , P Saenger , JM Wit , J Woelfle

To read the full abstract: Horm Res Paediatr. 2019;92:1–14In March 2019, 46 international experts from 14 countries across 5 continents attended a 3-day workshop organized by the Growth Hormone Research Society (GRS) and produced this perspective on the diagnosis, management and therapy in children with short stature. In this context, this expert panel tackled almost all aspects related to the management of children with short stature, prov...